Skip to content

Can a Blood Test Detect 50 Types of Cancer?

CancerSnoop Claim Check
Can a Blood Test Detect 50 Types of Cancer?

Verdict · MISLEADING

A blood test for 50 cancers looks for biological signals that may indicate cancer. A positive result needs follow-up. A negative result can miss cancer, and detecting a signal is a separate question from improving survival.

Claim Statement

One blood draw reliably diagnoses or rules out more than 50 cancers and can replace established screening.

Claim Origin

The wording compresses a panel’s intended scope, the accuracy of its result and the benefit of a screening program into one headline.

What does a blood test for 50 cancers actually measure?

A multi-cancer detection test measures biological signals in a blood sample. Some tests look for chemical patterns on tiny fragments of DNA released into the bloodstream. A model looks for patterns associated with cancer and may predict where the signal originated. It cannot inspect a suspicious organ. An evaluation may still need an examination, a scan, an endoscopy or tissue sampling. The NCI distinguishes the initial signal from the eventual diagnosis. [1]

Why two percentages can tell different stories

Sensitivity asks how often the test finds a signal among people who have cancer. Positive predictive value asks how often someone with a positive result is ultimately found to have cancer. Both answers depend on who was tested, the cancers they had and how the researchers determined whether cancer was present. A low false alarm rate can coexist with a substantial share of positive results that do not lead to a diagnosis, especially in a population where cancer is uncommon.

The PATHFINDER study followed what happened after testing in a prospective cohort. It assessed how test results led to diagnostic workups. That design can show what happens after a signal is found. It cannot, by itself, tell us how the same population would have fared without screening. [2]

What the NHS-Galleri trial found

The randomized NHS-Galleri trial compared adding the test to usual care with a control group. Its primary outcome looked at diagnoses of stage III and stage IV cancer together. The main comparison did not show a statistically significant reduction. A separate stage IV comparison favored the testing group. Both results can be true because they answer different questions. The trial group also published a companion paper on test performance. Neither paper should be read as showing that every listed cancer is detected reliably. [3] [4]

What to ask before you decide

Ask which result would change your care and who will coordinate any follow-up. Check how the test performed in people with an age and risk profile similar to yours. Ask for early-stage performance for a specific cancer if that is the reason you are considering the test. Continue the screening recommended for you, and bring persistent symptoms to your clinician even if a screening blood test comes back negative. If the test is offered outside a study, find out what diagnostic follow-up is available and who would pay for it.

What happens if the follow-up tests find nothing?

A positive signal may be followed by several tests without a confirmed cancer. Ask which clinician will interpret the results together and when the evaluation is considered complete. It helps to distinguish a false alarm from a workup where uncertainty remains. Before deciding on screening, ask how the service handles this outcome and which records you will receive to share with your regular clinician.

Treat a blood test for 50 cancers as one input to a screening decision. Ask what a result would add to the care you already receive.

Sources and References

  1. Questions and Answers about Multi-Cancer Detection Tests
  2. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study
  3. First full results from the NHS-Galleri trial published in leading journals
  4. Performance of a multi-cancer early detection test in the randomized controlled NHS-Galleri trial
SHARE THIS EVIDENCE
WhatsApp ↗
Back To Top